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Abstract 
Background: Ovarian cancer is the most frequent cause of death from gynecologic malignancies in the world. 
Ovarian cancer is predominantly a disease of postmenopausal period, with a median age at diagnosis of 59 years. 
In recent years, there have been many debates about the relationship between fertility medication and cancer. Due 
to the lack of comprehensive study of this matter, and as understanding the relationship between the use of fertility 
drugs and cancer is of importance, the present study was conducted to investigate the relationship between 
infertility drugs and cancer in women. Objective:  To determine the risk of ovarian cancer after treatment of 
infertility.  Study Selection: Multiple articles were reviewed. Prospective studies and case reports were excluded 
from the data. Retrospective studies were included in the study. Methods and Materials:  A review of the 
scientific literature concerning the association between the use of fertility treatments and the risk of ovarian cancer 
was done. In this study, digital databases including PubMed, EMBASE and Google scholar were searched. The 
survey was carried out using keywords such as “infertility”, “ ovarian cancer risk”, “gynecological cancer”, 
“gynecological cancer risk”, “cancer risk”, “in vitro fertilization”, “progesterone”, “fertility drugs”, “infertility 
treatment”, variously associated together. Results: Using the search criteria, 25 researches were examined based 
on the title and abstract. All the 25 studies were considered in their full versions. Of these works, including 
literature reviews or meta-analysis reports, it was concluded that infertility treatment has a positive relationship 
with ovarian cancer. Conclusion: The results of this study suggest that fertility drug usage significantly contribute 
to overall risk of ovarian cancer when adjusting for known confounding factors. In the next years, the incidence 
of female infertility is expected to increase. A lot of new drugs are under investigation while other recent drugs 
are already in current use. More study can be done so that the mortality and mobility could be reduced in the 
society. 
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Introduction:  
Infertility is a common condition, which affects ∼10–15% of all couples in the world.1 During the past three 
decades, the use of fertility treatments, including intrauterine insemination, in vitro fertilization (IVF) etc. has 
increased constantly in western countries.2 The increased use of fertility drugs has given rise to studies of their 
potential adverse health effects and, especially, their potential to cause cancer.3 Several epidemiological studies 
addressed the potential connection between the use of fertility drugs and risk for ovarian cancer. Ovarian cancer 
is multifactorial and complex in etiology. Lifestyle factors shown to increase the risk of ovarian cancer include 
low parity4, late onset of menopause5, and perineal talc use.6 Oral contraceptive use, breastfeeding, and tubal 
ligation have been shown to have a protective effect on ovarian cancer risk.7 Several theories have been proposed 
to explain the mechanisms by which these factors affect risk of ovarian cancer.8 The incessant ovulation hypothesis 
theorizes that the repeated damage and subsequent repair cycles that occur during ovulation on the epithelial 
surface of the ovary contributes to DNA damage and increases the risk of developing ovarian cancer.9 The 
gonadotropin hypothesis postulates that exposure to high levels of circulating pituitary gonadotropins, which 
stimulates the ovarian surface epithelium, plays a role in the development of ovarian cancer.10 Both of these 
theories suggest that the use of fertility drugs, which often contain gonadotropins and stimulate ovulation, may 
increase the risk of ovarian cancer. Fertility drug use has increased markedly in the world. The use of infertility 
services was more common among older women and women who were childless. Despite the growing number of 
women seeking fertility treatment, the effects of fertility drug use on ovarian cancer risk remain uncertain.11  
The increasing use of fertility drugs necessitates the separation of the effects of underlying infertility and 
other confounding factors from those of fertility drug use. This study is one of the largest case–control studies of 
ovarian cancer conducted to date. The aim is to determine the risk of ovarian cancer after treatment of infertility.  
 
Study Selection 
Multiple articles were reviewed. Prospective studies and case reports were excluded from the data. Retrospective 
studies were included in the study. 
 
 
Journal of Health, Medicine and Nursing                                                                                                                                          www.iiste.org 






Using the search criteria, 25 researches were examined based on the title and abstract. All the 25 studies were 
considered in their full versions. Of these works, including literature reviews or meta-analysis reports, it was 
concluded that infertility treatment has a positive relationship with ovarian cancer. 
 
Discussion 
This study shows that there is a positive relationship between fertility drugs and ovarian cancer.  Early studies that 
reported an increased risk of ovarian cancer among fertility drug users included small numbers of ovarian cancer 
patients exposed to fertility drugs and were unable to adjust for risk factors known to impact ovarian cancer risk.12 
A previous study showed that the infertile women in cohort are at a higher risk of ovarian cancer than women in 
the general Danish population, even after adjustment for parity.13 
The collaborative analysis of 12 case-control studies in the United States5 suggested that infertile women 
who received fertility drugs but remained nulliparous may be at particularly high risk. This result is in line with 
those of two subsequent studies that found statistically non-significantly increased risks among women who 
remained nulliparous. However, our study, in line with others, found no association between overall risk of ovarian 
cancer and use of fertility drugs after stratifying for parity.14 
In a retrospective study Brinton et al. evaluated 12193 infertile women followed for a median of 18.8 years 
and reported 45 ovarian cancers. This study used a detailed collection of information about drug exposures, causes 
of infertility, and other potential cancer risk factors.15 
Lerner-Geva et al. presented a study to evaluate the possible risk for cancer development in a cohort of 2431 
women who were treated for infertility with gonadotropins and other fertility drugs in Israel, with over 30 years 
of follow-up. They calculated the SIR between the observed cancer cases and the expected cancer rates in the 
general population. The investigators observed 18 cases of ovarian tumors compared to 18.1 expected (SIR 1.0; 
95% CI: 0.59-1.57). Ovarian cancer risk was not found to be elevated and the authors were not able to demonstrate 
a significant high risk associated with ovulation stimulating treatments.16 
 
Conclusion 
The results of this study suggest that fertility drug usage significantly contribute to overall risk of ovarian cancer 
when adjusting for known confounding factors. In the next years, the incidence of female infertility is expected to 
increase. A lot of new drugs are under investigation while other recent drugs are already in current use. More study 
can be done so that the mortality and mobility could be reduced in the society. 
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